제약 CDMO 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Pharmaceutical CDMO Market was valued at USD 173.7 billion in 2025 and is estimated to grow at a CAGR of 7.1% to reach USD 342 billion by 2035.

Expansion of the Pharmaceutical CDMO Market is driven by rising outsourcing activities among both established pharmaceutical companies and emerging biotechnology firms, growing demand for biologics, and limited manufacturing capacity across specialized production segments. Organizations are increasingly focusing resources on core functions such as research, development, commercialization, and market expansion while delegating manufacturing operations to specialized service providers. This trend continues to strengthen demand across the pharmaceutical outsourcing value chain. At the same time, evolving regulatory requirements, increasing quality expectations, and growing operational complexity are reshaping the competitive landscape. Capacity limitations in advanced manufacturing environments and the need for specialized production expertise further support market growth. Contract development and manufacturing organizations are also navigating a more rigorous regulatory environment characterized by heightened emphasis on quality management, data integrity, supply chain visibility, and compliance standards. As pharmaceutical pipelines become more complex and diversified, the role of CDMOs in supporting efficient product development and commercial manufacturing continues to expand across global healthcare markets.

The contract manufacturing services segment held a 48.7% share in 2025. This category includes large-scale manufacturing activities conducted under long-term agreements between CDMOs and pharmaceutical or biotechnology companies. The segment's dominance reflects the increasing reliance on outsourced manufacturing models across both innovative and established drug portfolios. As pharmaceutical companies continue to optimize operational efficiency and reduce capital investment requirements, contract manufacturing services remain a critical component of industry growth. The expansion of outsourced production activities across multiple therapeutic categories is expected to support continued demand for these services throughout the forecast period.

The packaging and labeling services segment accounted for 12.4% share in 2025. This segment includes primary and secondary packaging operations, serialization solutions, product tracking systems, clinical packaging services, and specialized pharmaceutical packaging formats. The growing complexity of pharmaceutical supply chains and increasing regulatory requirements related to product traceability have elevated the importance of packaging and labeling services within the market. Pharmaceutical companies are increasingly seeking partners capable of delivering compliant, scalable, and efficient packaging solutions while ensuring product security and supply chain transparency. As regulatory expectations continue to evolve, demand for advanced packaging and labeling capabilities is expected to increase steadily.

North America Pharmaceutical CDMO Market held a 39.1% share in 2025. The region's leadership position is supported by a strong concentration of pharmaceutical and biotechnology companies, substantial research and development activity, and a well-established contract manufacturing infrastructure. Continued investment in innovative therapies, expanding drug development pipelines, and strong commercialization activity are contributing to sustained demand for outsourced pharmaceutical services. In addition, the region benefits from a highly developed regulatory framework, advanced manufacturing capabilities, and ongoing investments in production capacity, further strengthening its position within the global market.

Major companies operating in the Global Pharmaceutical CDMO Market include Thermo Fisher Scientific, Lonza Group AG, Samsung Biologics, Catalent, WuXi Biologics Co., Ltd., Boehringer Ingelheim, Recipharm, Piramal Pharma Solutions, Siegfried Holding, CordenPharma International, Cambrex, PCI Pharma Services, Fujifilm Diosynth Biotechnologies, Almac Group, Syngene International, and Abzena. Companies competing in the Pharmaceutical CDMO Market are implementing a range of strategic initiatives to strengthen their market presence and expand service capabilities. Capacity expansion remains a key focus, with organizations investing in new manufacturing facilities, advanced production technologies, and specialized infrastructure to meet growing customer demand. Many companies are increasing investments in biologics manufacturing, high-value therapeutic production, and advanced pharmaceutical technologies to address evolving industry requirements. Strategic acquisitions, partnerships, and long-term customer agreements are also being utilized to broaden service portfolios and enhance geographic reach.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
  • 2.1.1 Business trends
  • 2.1.2 Service trends
  • 2.1.3 Product trends
  • 2.1.4 Molecule type trends
  • 2.1.5 Therapeutic area trends
  • 2.1.6 End use trends
  • 2.1.7 Regional trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing outsourcing by pharmaceutical and biotech companies
    • 3.2.1.2 Growing biologics and advanced therapy pipeline
    • 3.2.1.3 Capacity constraints and need for specialized infrastructure
    • 3.2.1.4 Rising R&D investments and drug approvals globally
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory complexity and compliance burden
    • 3.2.2.2 Pricing pressure and competition
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of next-generation modalities (CGT, mRNA, ADCs)
    • 3.2.3.2 Strategic partnerships and long-term outsourcing contracts
• 3.3 Growth potential analysis
• 3.4 Technology and innovation landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Pricing trend analysis (Driven by primary research)
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 MEA
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.11 Investment & funding analysis (Driven by primary research)
• 3.12 Pharmaceutical CDMO total addressable market size, 2022 - 2035

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Service, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Contract development
• 5.3 Contract manufacturing
• 5.4 Packaging and labelling
• 5.5 Regulatory support & quality services
• 5.6 Other services

Chapter 6 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 API
  • 6.2.1 Chemical APIs
  • 6.2.2 Biological APIs
  • 6.2.3 High potency APIs
• 6.3 Finished drug formulations (FDF)
  • 6.3.1 Solid dose
  • 6.3.2 Semi solid dose
  • 6.3.3 Liquid
  • 6.3.4 Other dosage forms

Chapter 7 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Small molecule
• 7.3 Large molecule

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Metabolic and endocrine
• 8.4 Cardiovascular
• 8.5 CNS and psychiatry
• 8.6 Infectious diseases and vaccines
• 8.7 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical companies
• 9.3 Biotechnology companies
• 9.4 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 UK
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Lonza Group
• 11.2 Boehringer Ingelheim
• 11.3 Thermo Fisher Scientific
• 11.4 Catalent
• 11.5 Samsung Biologics
• 11.6 WuXi Biologics
• 11.7 Recipharm
• 11.8 Siegfried
• 11.9 CordenPharma International
• 11.10 Piramal Pharma Solutions
• 11.11 Cambrex
• 11.12 Fujifilm Diosynth Biotechnologies
• 11.13 PCI Pharma
• 11.14 Almac Group
• 11.15 Abzena
• 11.16 Syngene International